In addition, GLP-1 RAs are particularly effective in reducing HbA1c, which is especially relevant as HbA1c levels 6.5% have been shown to be associated with increased incidence of microvascular complications [69] while it is challenging to achieve HbA1c levels 30 ml/min/1.73 m 2 [2], with a GLP-1 RA as the preferred agent if additional therapy is needed for glycemic control
Some patients report reduced hunger and earlier satiety within the first week of GLP-1 treatment, though individual response varies considerably
98% of our patients would recommend us to their friends and family
It has the longest track record, the most extensive post-market safety data, cardiovascular outcome evidence, and broad availability
The therapeutic range extends to 15 mg
According to the company's website, MadeMed currently serves patients in 40 states